Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Transcode Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 19 | 9 | −10 |
| Shares | 2.14M | 30.4K | −2.11M (−98.6%) |
| Value | $1.06M | $237.0K | −$823.1K (−77.6%) |
New holders (1)
Institutions that held Transcode Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Goldman Sachs Group Inc | 28,042 | $218.7K | 0.00% |
Sold out (11)
Institutions that held Transcode Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Anson Funds Management LP | 1,462,112 | $723.7K |
| Sabby Management, LLC | 229,052 | $113.4K |
| Warberg Asset Management LLC | 50,000 | $24.8K |
| Corsair Capital Management, L.P. | 40,000 | $19.8K |
| Commonwealth Equity Services, LLC | 21,674 | $11.0K |
| Acadian Asset Management LLC | 22,323 | $11.0K |
| Ground Swell Capital, LLC | 14,363 | $7.11K |
| Marex Group plc | 12,678 | $6.28K |
| Morgan Stanley | 5,000 | $2.48K |
| Danske Bank A/S | 1 | $0 |
| BlackRock, Inc. | 1 | $0 |